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Background: HTRA1 has been associated with 
intervertebral disc (IVD) degeneration although its 
role is unknown. 
Results: HTRA1 upregulated matrix 
metalloproteinase (MMP) production by IVD cells 
via the generation of fibronectin fragments.  
Conclusion: HTRA1 plays a detrimental role in 
the pathogenesis of IVD degeneration. 
Significance: HTRA1 may represent a novel 
therapeutic target for the treatment of spinal disc 
degeneration. 
 
SUMMARY 
Human HTRA1 is a highly conserved 
secreted serine protease that degrades 
numerous extracellular matrix (ECM) proteins. 
We have previously identified HTRA1 as being 
upregulated in osteoarthritic patients and as 
having the potential to regulate matrix 
metalloproteinase (MMP) expression in 
synovial fibroblasts through the generation of 
fibronectin fragments. In the present report, we 
have extended these studies and investigated 
the role of HTRA1 in the pathogenesis of 
intervertebral disc (IVD) degeneration. HTRA1 
mRNA expression was significantly elevated in 
degenerated disc tissue and was associated with 
increased protein levels. However, these 
increases did not correlate with the appearance 
of rs11200638 single nucleotide polymorphism 
(SNP) in the promoter region of the HTRA1 
gene, as has previously been suggested. 
Recombinant HTRA1 induced MMP 
production in IVD cell cultures through a 
mechanism critically dependent on MEK, but 
independent of IL-1β  signaling.  The use of a 
catalytically-inactive mutant confirmed these 
effects to be primarily due to HTRA1 serine 
protease activity. HTRA1-induced fibronectin 
proteolysis resulted in the generation of various 
sized fragments, which when added to IVD cells 
in culture, caused a significant increase in 
MMP expression. Furthermore, one of these 
fragments was identified as being the amino-
terminal fibrin- and heparin-binding domain, 
and was also found to be increased within 
HTRA1-treated IVD cell cultures as well as in 
disc tissue from patients with IVD 
degeneration. Our results therefore support a 
scenario in which HTRA1 promotes IVD 
degeneration through the proteolytic cleavage 
of fibronectin and subsequent activation of 
resident disc cells. 
Degeneration of the intervertebral disc 
(IVD) is now regarded as being one of the major 
causes of low back pain (LBP), which is a highly 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M112.341032The latest version is at 
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prevalent, debilitating and costly disorder (1,2). 
The pathogenesis of degeneration is a highly 
complex and poorly understood process with many 
different genetic, biological and mechanical 
influences playing key roles in the breakdown of 
extracellular matrix (ECM) components (3). The 
predominant means by which ECM is degraded is 
thought to be due to the proteolytic actions of 
matrix metalloproteinases (MMPs) and 
aggrecanases (ADAMTS). A number of MMPs, 
including MMP-1, -3, -7, -9 and -13, as well as 
ADAMTS-4, have been shown to increase in the 
IVD during disc degeneration and are responsible 
for the breakdown of several matrix components, 
most notable being aggrecan and collagen (4-7). 
Both MMPs and their inhibitors (TIMPS 1, 2 and 
3) have been localized to the resident chondrocyte-
like cells of the nucleus pulposus and inner 
fibrosus compartments of the IVD (4) thus 
implicating these cells in disease pathogenesis. 
The secretion of MMPs by human IVD cells is 
mediated in part through the stimulatory effects of 
various pro-inflammatory cytokines, the most 
prominent of which being IL-1β (8). In addition, 
fibronectin peptide fragments of the ECM have 
also been shown to induce MMP production by 
IVD cells (9) and are potent instigators of 
experimental disc degeneration (10). Moreover, 
fibronectin fragments have been shown to 
accumulate in the IVD during degeneration (11) 
although the proteases responsible for their 
formation remain elusive.  
Human HTRA1 belongs to a well-defined 
family of serine proteases originally identified in 
bacteria (12). Although primarily regarded as 
being a key regulator of tumor development and 
subsequent malignancies (13-15), a growing body 
of evidence now exists to suggest that HTRA1 
may also play a central role in determining the 
outcome of various musculoskeletal disease 
pathologies including Duchenne Muscular 
Dystrophy (DMD) (16), osteoarthritis (17-19) and 
rheumatoid arthritis (19, 20). It has recently been 
shown in a Japanese population study that a single 
nucleotide polymorphism (SNP) located within the 
HTRA1 promoter is associated with spinal disc 
degeneration where increases in spinal disc 
narrowing were observed in patients without the G 
allele (AA) as compared to those bearing at least 
one G allele (GG + GA) (21). It would therefore 
appear that HTRA1 may also play a role in disc 
pathology, although its influence on disease and its 
mechanism of action have not yet been elucidated.  
Observations from our own studies 
examining the role of HTRA1 in osteoarthritis 
imply that HTRA1 may actually have a 
detrimental effect on the pathogenesis of 
musculoskeletal disease. Elevated levels of 
HTRA1 protein were measured in the synovial 
fluid from osteoarthritic patients and primary 
synovial fibroblasts isolated from diseased patients 
were identified as being a major source of HTRA1 
(19). The addition of proteolytically active 
HTRA1 to fibroblast cultures resulted in marked 
upregulation of various MMPs including MMP-1 
and MMP-3, both of which have been implicated 
in cartilage and joint destruction in arthritic 
patients. Further experiments confirmed that the 
stimulatory effects of HTRA1 on MMP expression 
were protease-dependent and were related to the 
formation of fibronectin fragments due to 
extracellular degradation. Such observations are 
therefore strongly suggestive of a central role for 
HTRA1 in joint degeneration through its 
proteolytic actions on ECM components and thus 
may also be indicative of its role in other disease 
pathologies, such as disc degeneration.  
In the current study, we used IVD tissue 
and cell samples from surgical patients in order to 
further investigate the potential involvement of 
HTRA1 in IVD degeneration. Our findings 
implicate HTRA1 as a key factor in the underlying 
pathology associated with IVD degeneration. 
HTRA1 may therefore represent a novel target for 
the development of more effective therapeutic 
strategies to treat this debilitating condition. 
 
EXPERIMENTAL PROCEDURES 
Materials–Human fibronectin and rabbit 
IgG were purchased from R & D Systems 
(Abingdon, UK).  IL-1RA was obtained from 
Abcam (Cambridge, UK) and MEK1/2 inhibitors 
PD98059 and U0126 were from Sigma-Aldrich 
(Buchs, Switzerland). Monoclonal antibodies 
against the fibronectin carboxyl-terminal heparin 
binding domain (Mab1935) and the amino-
terminal fibrin- and heparin-binding domain 
(Mab1936) were from Chemicon International. A 
polyclonal anti-HTRA1 antibody was generated as 
previously described (19). All anti-IgG 
horseradish peroxidase (HRP)-conjugated, 
fluorescence-conjugated secondary antibodies and 
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normal serum were from Jackson 
ImmunoResearch (Suffolk, UK). DAPI was 
purchased from Sigma-Aldrich. Collagenase NB4  
was purchased from Serva/Promega (Duebendorf, 
Switzerland) and dispase II from Roche 
Diagnostics (Rotkreuz, Switzerland). 
Tissue Harvesting–IVD tissue and/or 
blood was obtained from a total of 39 patients 
undergoing spinal surgery for symptomatic 
degenerative disc disease, disc herniation or spinal 
trauma following informed consent in accordance 
with the local ethical guidelines (carried out at the 
SRH Clinic Karlsbad-Langensteinbach, Karlsbad, 
Germany). The degree of IVD degeneration in 
patients was assessed prior to surgical intervention 
by magnetic resonance imaging (MRI) using a 4-
level grading system based on Pfirrmann’s 
classification of disc degeneration (22). 
Degeneration grades were assigned as follows; 
grade 1, non-degenerated (normal disc height); 
grade 2, mild degeneration (slight decrease in disc 
height); grade 3, moderate degeneration (moderate 
decrease in disc height); grade 4, severe 
degeneration (collapsed disc space). 
Isolation and Culture of IVD Cells–
Human IVD cells were isolated from the discs of a 
total of 14 patients undergoing spinal surgery for 
disc herniation (carried out at Balgrist University 
Hospital, Zürich, Switzerland) as previously 
described (23). Briefly, IVD tissue was 
enzymatically digested (0.2% collagenase NB4, 
0.3% dispase II) for 4–8 h and cells were 
thereafter cultured in growth medium consisting of 
DMEM/F12 supplemented with 10% FCS, 
penicillin (50 units/ml), streptomycin (50 µg/ml) 
and amphotericin B (25 µg/ml) and incubated at 
37°C with 5% CO2 and used at passages 2 to 3. 
Recombinant Human HTRA1–Purified 
recombinant his-tagged HTRA1 in which the 
amino-terminal mac25 homology domain was 
absent (termed HTRA1Δmac) was produced in 
Escherichia coli and purified using Ni2+-NTA 
chromatography as previously described (19, 24). 
The enzymatically inactive mutated form of 
HTRA1Δmac, termed  HTRA1ΔmacSA, was 
generated through conversion of residue serine 
328 to alanine by mutagenesis. 
Stimulation of IVD Cells with 
Recombinant HTRA1–IVD cells were cultured in 
6-well plates at 3.5 x105 cells per well and growth 
rested in serum-free medium for 2 h prior to 
stimulation. Cells were incubated in medium alone 
or medium supplemented with either 
HTRA1Δmac (5 µg/ml) or HTRA1ΔmacSA (5 
µg/ml) for up to 24 h. Concentrations used were 
based on previous observations using human 
synovial fibroblasts (HSFs) (19). After this time, 
RNA and culture supernatants were harvested for 
further analysis. In the case of inhibition studies, 
IVD cells were pre-incubated with either PD98059 
(10 µM), U0126 (10 µM) or IL-1RA (250 ng/ml) 
for 2 h prior to stimulation.   
Quantitative Real-Time PCR (qRT-PCR)–
Total RNA was isolated from either intact IVD 
tissue or cells and purified using TRIzol reagent 
(Invitrogen AG, Basel, Switzerland) according to 
the manufacturer’s instructions. RNA (0.5 µg) was 
reverse transcribed to cDNA using superscript II 
(Invitrogen AG) and random hexanucleotide 
primers (Promega AG, Dübendorf, Switzerland). 
Quantification of mRNA expression was 
performed with TaqMan Gene Expression Assays 
(Applied Biosystems, Rotkreuz, Switzerland) 
(Supplementary Table 1) using the StepOnePlus 
Real-Time PCR System (Applied Biosystems) and 
values normalized to GAPDH mRNA levels and 
presented as fold change according to the 2-∆∆CT 
method. In cases where individual patients (n = 
36) were compared for expression levels of 
HTRA1 and FN mRNA in IVD tissue, data was 
normalized to TBP and presented as 2-∆CT. Each 10 
µl reaction consisted of 1x TaqMan Fast Universal 
PCR Master Mix (Applied Biosystems), 1x 
TaqMan Gene Expression Assay and 10 ng cDNA 
(based upon initial RNA concentrations). All 
reactions were performed in triplicate in fast 
optical 96-well reaction plates (Applied 
Biosystems) at 95oC for 20 seconds and 40 cycles 
of 95oC for 1 second and 60oC for 20 seconds. 
SNP Analysis–A total of 35 patients were 
genotyped using a TaqMan SNP Genotyping 
Assay specific for the SNP, rs11200638, according 
to the manufacturer’s instructions (Applied 
Biosystems). Patients were grouped according to 
their individual genotypes and association studies 
performed in order to determine the influence of 
the rs11200638 (A) risk allele on susceptibility to 
IVD degeneration. The influence of rs11200638 
on HTRA1 expression in IVD tissue was also 
assessed in patients from whom both RNA and 
DNA samples were obtained (n = 32). 
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Western Blot Analysis of Patient IVD 
tissue–Patient IVD samples (n = 12) were selected 
based on degeneration grade. Protein was 
extracted using CelLytic M (Sigma-Aldrich) 
containing a protease inhibitor cocktail (Sigma-
Aldrich) and protein amounts determined initially 
by BioRad Protein Assay (BioRad, Reinach, 
Switzerland). Protein samples were boiled for 5 
min in loading buffer (50 mM Tris-HCl, pH 6.8, 
2% SDS, 10% glycerol, 100 mM DTT, 0.002% 
Bromophenol blue) and equal amounts of protein 
loaded onto 12% SDS-PAGE gels. Further 
corrections to the loading volumes were made 
following densitometric analysis of Coomassie 
Blue stained gels, thus allowing for accurate 
comparisons to be made between individual 
patient samples. Protein was then electroblotted 
onto PVDF membranes using the Trans-Blot 
Turbo blotting system (BioRad) and incubated in 
5% skimmed milk, 50 mM Tris-HCl, pH 7.6, 150 
mM NaCl, 0.1% Tween 20 (TBST) for 1 h at room 
temperature. Membranes were then incubated for 
1 h at room temperature with either rabbit anti-
human HTRA1 (1:2000) or mouse-anti fibronectin 
amino-terminal fibrin- and heparin-binding 
domain (Mab1936) (1 µg/ml). After washing in 
TBST three times for 5 min each, membranes 
were incubated with a HRP-conjugated anti-mouse 
or anti-rabbit IgG (1:10’000) for 1 h at room 
temperature. Following a further washing step, 
peroxidase activity was detected using 
SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Lausanne, 
Switzerland).  
Immunofluorescence Microscopy–Unfixed 
frozen IVD tissue sections were air dried for 20 
minutes, blocked with normal goat serum (1:10) 
and incubated with polyclonal anti-HTRA1 (1:50) 
or control rabbit IgG (2 µg/ml) in phosphate 
buffered saline (PBS), pH 7.3, 1% BSA for 16 h at 
4oC. Tissue samples containing HTRA1 were then 
identified using goat anti-rabbit-Cy3 (1:400). 
Sections were mounted in Mowiol/DABCO 
(Sigma-Aldrich) containing DAPI (0.5 g/ml) and 
images captured using the Leica DMI6000B 
automated inverted research microscope system 
(Leica Microsystems). 
Quantification of Secreted MMP-3–MMP-
3 protein levels in culture supernatants were 
determined using an MMP-3-specific ELISA kit 
according to the manufacturer’s instructions (R & 
D Systems). 
Proteolytic Enzyme Assays–Degradation 
of fibronectin by HTRA1Δmac was determined 
using methods previously described (19). Briefly, 
an equimolar ratio of HTRA1Δmac and 
recombinant human fibronectin were incubated 
together in TBS, pH 8.5, for 16 h at 37 °C. In 
some reactions,   HTRA1Δmac was replaced by 
proteolytically inactive HTRA1ΔmacSA. 
Fibronectin, HTRA1Δmac and HTRA1ΔmacSA 
were also incubated separately under the same 
conditions and served as controls. In order to 
assess whether HTRA1Δmac could also generate 
fibronectin fragments in IVD cell cultures, 
supernatants (20 ml) were harvested from cells 
treated with HTRA1Δmac  (5µg/ml) or 
HTRA1ΔmacSA  (5µg/ml) for 24 h and 
concentrated using Amicon Ultra-15, 10 kDa 
mwco filter units (Millipore). Fibronectin 
fragments were analyzed on 4-15% Mini-
PROTEAN TGX Precast gels (BioRad) by 
Coomassie Blue staining and immunoblotting 
using either mouse-anti fibronectin carboxyl-
terminal heparin binding domain (Mab1935) (1 
µg/ml) or mouse-anti fibronectin amino-terminal 
fibrin- and heparin-binding domain (Mab1936) (1 
µg/ml) as described above. The EnzCheck 
Elastase Kit (Molecular Probes, Basel, 
Switzerland) was used to confirm the proteolytic 
activity of recombinant  HTRA1 proteins 
according to the manufacturer’s protocol.  
Effect of Fibronectin Fragments on MMP 
Expression–Equimolar concentrations of 
fibronectin (20 µg) and HTRA1Δmac (5 µg) were 
incubated under the conditions described above. 
Control reactions were also performed and 
included TBS, pH 8.5, alone or in combination 
with either fibronectin or  HTRA1Δmac. Samples 
were then diluted into equilibration buffer 
containing TBS, pH 7.6, with 20 mM imidazole 
and incubated with 50 µl pre-equilibrated HisPur 
Ni2+-NTA resin (Qiagen, Hombrechtikon, 
Switzerland) in spin columns (Thermo Scientific) 
for 1 h at 4oC. Columns were then centrifuged for 
5 min at 1600 rpm and the affinity column flow-
through fraction collected, dialyzed in TBS for 4 h 
at 4oC using Slide-A-Lyzer MINI Dialysis Devices 
(3.5K mwco) (Thermo Scientific) and then 
incubated with IVD cells for up to 24 h after 
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which time MMP expression was evaluated by 
qRT-PCR. 
Statistical analysis–All statistical analyses 
were carried out using SPSS19.0 (SPSS Inc., 
Chicago, IL). Parametric analysis of normally 
distributed data was performed using the two-
tailed unpaired Student’s t-test or one-way 
analysis of variance (ANOVA) followed by 
Tukey’s post-hoc tests for multiple group 
comparisons. The Pearson’s correlation coefficient 
was used to evaluate the relationship between the 
expression levels of selected genes in patient 
tissue samples. The chi-square test was used to 
compare allele frequencies in patients with or 
without IVD degeneration (1 degree of freedom). 
In all cases, a p-value of < 0.05 was considered 
statistically significant. 
 
RESULTS 
 We have previously demonstrated that 
HTRA1 plays a central role in the regulation of 
MMP expression in synovial fibroblasts from 
arthritic patients and that its stimulatory effects 
may be linked to the generation of fibronectin 
fragments (19). In the present report, we further 
investigated this property of HTRA1 in IVD cell 
cultures and aimed to establish its potential role in 
IVD degeneration.   
Identification of HTRA1 in Patient Tissue– 
HTRA1 mRNA levels within IVD tissue samples 
from patients with varying degrees of disc 
degeneration were normalized to TBP and 
presented as 2-∆CT. Expression levels significantly 
correlated (r = 0.375; p = 0.024) with patient 
degeneration grade and were found to be markedly 
increased in patients with severity scores of 3 (4-
fold; p = 0.015) and 4 (3-fold; p = 0.2) as 
compared to control patients (Fig. 1A). Western 
blot analysis of IVD protein samples using a 
polyclonal antibody against HTRA1 identified two 
main species of HTRA1 protein migrating at ~50 
kDa (closed arrow head) and ~42 kDa (open 
arrow head), which most likely represented the 
full length and processed forms of HTRA1 
respectively (Fig. 1B and supplementary Fig. S1) 
(25). The 50 kDa HTRA1 was found at varying 
levels in the majority samples tested whilst the 42 
kDa form of HTRA1 was identified in degenerated 
IVD protein samples only and was noticeably 
increased in the more severely affected discs. 
HTRA1 protein was also identified within both the 
cells and ECM of frozen IVD tissue sections as 
determined by immunofluorescence staining, and 
levels were found to be increased in the more 
severely affected patients as compared to  the 
control trauma patients (Fig. 1C) 
Analysis of Patient rs11200638 SNP 
Genotype–In light of the recent evidence linking 
the rs11200638 SNP (G>A) in the HTRA1 gene 
promoter and spinal disc degeneration in Japanese 
women (21), we investigated whether the 
rs11200638 risk allele frequency between patient 
groups used in the current study was associated 
with susceptibility to IVD degeneration. DNA 
from a total of 35 patients was subjected to SNP 
genotyping using the TaqMan SNP Genotyping 
Assay specific for  rs11200638 SNP. Contrary to 
previous expectations, we were unable to 
demonstrate any significant differences in SNP 
allele frequencies between control patients without 
disc degeneration (25%) and patients with 
degeneration grades of 2 (14.3%; p = 0.4), 3 (15%; 
p = 0.37) or 4 (15%; p = 0.37) (Table 1). We also 
performed a comparative analysis of HTRA1 
expression levels in IVD tissue from 32 patients of 
known genotype. However, no significant 
associations could be made between HTRA1 
expression levels and the rs11200638 genotype 
(Table 1). 
Effect of Recombinant HTRA1 on MMP 
Production by IVD Cells–In order to investigate 
how HTRA1 may contribute to IVD degeneration, 
we generated both proteolytically active and 
inactive recombinant forms of HTRA1 lacking the 
amino-terminal mac25 homology domain as 
previously described (19). The protease activity of 
the active protein, termed HTRA1Δmac, was 
confirmed by its ability to cleave purified bovine 
elastin and was dependent on both incubation time 
(Fig. 2A) and protein amount (Fig. 2B). No such 
activity was observed with the proteolytically 
inactive form of HTRA1 (HTRA1ΔmacSA) in 
which serine 328, part of the serine protease 
catalytic triad domain, had been substituted for 
alanine. The effects of these recombinant proteins 
on MMP production by cultured IVD cells was 
then investigated. Cells were incubated for up to 
24 h with either  HTRA1Δmac (5 µg/ml) or 
HTRA1ΔmacSA (5 µg/ml) and the fold change in 
mRNA expression levels of MMP1, MMP3 and 
MMP13 was determined by qRT-PCR. 
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HTRA1Δmac induced a significant increase in the 
expression levels of MMPs tested as compared to 
untreated cells and cells treated with the 
proteolytically inactive HTRA1ΔmacSA (Fig. 2C, 
D and E). In addition, HTRA1Δmac also enhanced 
the expression of ADAMTS4 (aggrecanase-1) 
although no increase was observed in MMP2 
(gelatinase A) expression and ACAN (aggrecan) 
expression was actually reduced (supplementary 
Fig. S2). MMP expression was also upregulated in 
HTRA1ΔmacSA-treated cells, although expression 
levels were over 3- to 7-fold less than those 
observed in cells incubated with HTRA1Δmac and 
were not deemed statistically significant as 
compared to untreated control cells (MMP1, p = 
0.19; MMP3, p = 0.41; MMP13, p = 0.41). Clearly 
therefore, HTRA1-induced MMP expression in 
IVD cells is primarily a protease-dependent 
phenomenon, although it would appear that other 
routes of activation may also exist. In addition to 
its stimulatory effects on MMP mRNA expression, 
HTRA1Δmac also enhanced MMP protein 
production as evidenced by results obtained from 
the MMP-3 ELISA (Fig. 2F). Low levels of 
secreted MMP-3 were detected in the supernatants 
of untreated cells (0.76 ng/ml ± 0.04) but became 
significantly elevated following stimulation with 
HTRA1Δmac (11.33 ng/ml ± 0.68; p < 0.001). As 
with our previous findings, these stimulatory 
effects of HTRA1 were significantly diminished 
following inactivation of its protease activity, 
although levels remained elevated as compared to 
untreated cells (2.23 ng/ml ± 0.13; p  = 0.089).  
Influence of MEK and IL-1β Inhibition on 
HTRA1–Induced MMP Production– Of the known 
instigators of MMP expression by IVD cells, IL-
1β is considered to be the most potent, and as 
such, is centrally involved in both IVD cell 
activation and IVD degeneration (8). Furthermore, 
IL-1β has previously been shown to play a central 
role in mediating MMP production by fibronectin 
fragments in cultures of bovine articular cartilage 
(26). We therefore investigated if the expression of 
IL-1β, along with several other cytokines 
including IL-6 and IL-8, was upregulated in IVD 
cells by HTRA1Δmac and whether this had any 
influence on the induction of MMP expression by 
HTRA1Δmac. Indeed, expression levels of the 
cytokines tested were upregulated in IVD cells 
stimulated with HTRA1Δmac (5 µg/ml), in a time 
dependent manner (Fig. 3A). However, additional 
studies focusing on the inhibition of IL-1β 
signaling using the IL-1 receptor antagonist (IL-
1RA) (250 ng/ml) failed to demonstrate any 
significant alterations in the ability of HTRA1 to 
induce MMP expression in IVD cells (Fig. 3B and 
supplementary Fig. S3). This would suggest that 
HTRA1 does not mediate its stimulatory effects 
through IL-1β production, although we cannot 
exclude the possibility that other cytokines may be 
involved.  
We have previously demonstrated that 
MMP expression by human synovial fibroblasts is 
upregulated in response to HTRA1 stimulation and 
that this was at least partly dependent on the 
generation of fibronectin fragments (19). 
Furthermore, fibronectin fragments were recently 
confirmed as being potent inducers of MMP 
expression in IVD cells, mediating their effects 
through activation of the MEK pathway (27). We 
therefore investigated whether inhibition of MEK 
could influence the actions of HTRA1 on IVD 
MMP expression. Indeed, inclusion of either of the 
specific MEK inhibitors PD98059 (10 µM) or 
U0126 (10 µM) 2 h prior to treatment with 
HTRA1Δmac (5 µg/ml), significantly abrogated 
its stimulatory effects on the expression of MMP1 
and MMP3 (Fig. 3C), thereby supporting the 
theory that fibronectin fragments may represent 
one possible route through which HTRA1 
mediates its stimulatory effects on IVD cells. 
Effect of Fibronectin Fragments on MMP 
expression by IVD cells–Based on the above 
results, we further investigated the potential 
involvement of fibronectin fragments in mediating 
the actions of HTRA1 on IVD cells. We observed 
a noticeable increase in the level of a 27-29 kDa 
fibronectin fragment containing the amino-
terminal fibrin- and heparin-binding domain in the 
supernatants from IVD cell cultures previously 
treated with HTRA1Δmac (5 µg/ml) as compared 
to cells incubated in medium alone or with the 
inactive  HTRA1ΔmacSA (5 µg/ml) (Fig. 4A and 
supplementary Fig. S4A). Interestingly, increases 
in fibronectin fragments containing the carboxyl-
terminal heparin binding domain were evident in 
both  HTRA1Δmac- and HTRA1ΔmacSA-treated 
cell cultures as compared to untreated controls. 
Further analyses confirmed that HTRA1Δmac, but 
not HTRA1ΔmacSA, could digest equimolar 
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concentrations of human plasma-derived 
fibronectin after a 16 h incubation period, resulting 
in various sized fragments being generated as 
determined by SDS-PAGE (Fig. 4B). The 
appearance of HTRA1Δmac as several bands is 
due to its autoproteolytic activity as previously 
described (19), an effect not observed with 
HTRA1ΔmacSA. Western blot analysis of the 
products generated from HTRA1Δmac-induced 
fibronectin proteolysis revealed the presence of 
numerous fragments containing the carboxyl-
terminal heparin binding domain, as well as the 
27-29 kDa fragment containing the amino-
terminal fibrin- and heparin-binding domain 
previously identified in the supernatants from 
HTRA1Δmac-treated IVD cells (Fig. 4C). We next 
investigated whether the fibronectin fragments 
generated by HTRA1 were also capable of 
activating IVD cells. Following an overnight 
incubation of human plasma-derived fibronectin 
with HTRA1Δmac (equimolar concentration), 
digested and undigested fibronectin was purified 
by affinity chromatography using Ni2+-NTA to 
remove the majority of his-tagged HTRA1Δmac 
(supplementary Fig. S4B) and then incubated for 
up to 24 h with IVD cells. The expression levels of 
MMP1, MMP3, and MMP13 (Fig. 4D) were all 
significantly increased in IVD cells incubated with 
the purified mixture of fibronectin fragments. By 
comparison, MMP expression in control cultures 
stimulated with the affinity column flow-through 
fraction from HTRA1Δmac samples in the absence 
of fibronectin was 6- to 9-fold less (p < 0.01), thus 
confirming that fibronectin fragments were the 
predominant cause of IVD cell activation.  
Association of Fibronectin Fragments 
with Disc Degeneration–Both fibronectin and 
fibronectin fragments  are known to increase with 
increasing disc degeneration and are thus 
considered to be an integral part of the underlying 
pathology (11). In the present study, fibronectin 
mRNA levels within IVD tissue samples from 
patients with varying degrees of disc degeneration 
were normalized to TBP and presented as 2-∆CT. 
Fibronectin expression levels within patient disc 
tissue samples were indeed elevated in response to 
increases in degeneration grade (Fig. 5A) and 
correlated significantly with HTRA1 mRNA 
expression levels (r = 0.856; p < 0.01) (Fig. 5B). 
Furthermore, Western blot analysis of IVD protein 
samples revealed an increase in fibronectin 
fragments containing the amino-terminal fibrin- 
and heparin-binding domain (Fig. 5C) in 
degenerated discs. Moreover, the majority of 
amino-terminal fragments identified were found to 
be of a similar size (27-29 kDa) to the fragment 
identified within samples of HTRA1-digested 
human fibronectin (lane 1). Membranes were 
counterstained with Coomassie Blue to confirm 
equal protein loading (Fig. 5D). 
 
DISCUSSION 
 In the current study, we have identified 
HTRA1 mRNA and protein in the intervertebral 
discs (IVD) of human subjects and demonstrated 
an association between expression levels and 
severity of IVD degeneration. HTRA1 has 
previously been linked with disc degeneration 
following the association of a single nucleotide 
polymorphism, rs11200638, in the HTRA1 gene 
and loss of disc height in postmenopausal 
Japanese women (21). In the present study, we 
were unable to show any significant association 
between the frequency of the risk allele (A) of 
SNP rs11200638 and IVD degeneration in a small 
European surgical patient population (n = 35). 
Furthermore, we found no evidence to suggest that 
the A allele of SNP rs11200638 has any 
significant influence on HTRA1 expression levels 
in IVD tissue. This is supported by findings from 
studies investigating the role of HTRA1 in age-
related macular degeneration (AMD) where, 
although closely associated with disease risk, 
rs11200638 alone was unable to significantly alter 
HTRA1 expression (28, 29). It was subsequently 
reported that the additional disruption of the 
adjacent gene, LOC387715, was necessary in 
order for rs11200638 to have a positive influence 
on HTRA1 expression (28). 
 We have previously shown that HTRA1 
has the potential to stimulate MMP production by 
HSFs thus implicating it in the pathogenesis of 
arthritis (19). As in the joints of arthritic patients, 
MMPs play a central role in orchestrating 
extracellular matrix (ECM) breakdown in discs of 
patients with IVD degeneration (4-7). Therefore, 
we next investigated whether HTRA1 could also 
influence MMP production in human IVD cells. 
Consistent with our earlier findings with HSFs, 
recombinant HTRA1 was able to induce the 
expression of MMP1, MMP3 and MMP13 mRNA, 
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as well as MMP-3 protein, in short term IVD cell 
cultures. In addition, we also observed a 
significant increase in ADAMTS4 expression in 
IVD cells stimulated with HTRA1. As with  
MMP-1, -3 and -13, ADAMTS-4 is also 
upregulated in degenerated discs (4), and may 
therefore represent an additional route through 
which HTRA1 could influence ECM breakdown. 
These stimulatory effects were found to be 
primarily reliant on HTRA1 protease activity as 
evidenced by the fact that the proteolytically 
inactive form of HTRA1 (HTRA1ΔmacSA) was 
unable to significantly enhance MMP production. 
Nevertheless, increases in MMP production were 
apparent in cultures treated with HTRA1ΔmacSA, 
and may be indicative of an additional, and as yet 
unidentified, protease-independent mechanism 
through which HTRA1 mediates its stimulatory 
effects. It is possible that further studies utilizing 
other mutant forms of HTRA1 may further assist 
in trying to decipher the exact cause of these 
stimulatory effects. 
Degradation of the ECM within 
degenerated IVDs can give rise to fibronectin 
fragments of various sizes, which themselves are 
capable of activating resident disc cells to produce 
matrix degrading proteases in a MEK-dependent 
manner (9, 27). Furthermore, the stimulatory 
properties of certain fibronectin fragment species 
on cellular MMP production are known to be 
mediated through the actions of IL-1β (26). In the 
current report, we demonstrated that the 
stimulatory effects of HTRA1 on MMP production 
by IVD cells was indeed MEK-dependent. 
Moreover, despite the fact HTRA1 induced the 
expression of IL1B, along with several other 
cytokines, inhibition of IL-1β signaling through 
the use of the IL-1RA failed to have any 
significant impact on HTRA1-induced MMP 
expression in IVD cells. On closer examination, it 
was revealed that IVD cell cultures and purified 
human plasma-derived fibronectin incubated with 
HTRA1Δmac both consisted of increased levels of 
a fibronectin fragment containing the 27-29 kDa 
amino-terminal fibrin- and heparin-binding 
domain. Furthermore, MMP expression was 
enhanced in IVD cells following stimulation with 
the proteolytic products of HTRA1-digested 
human plasma-derived fibronectin. Together with 
the additional observation that HTRA1-induced 
MMP expression was also dependent on MEK 
activity, we conclude that the stimulatory effects 
of HTRA1 on MMP production by IVD cells are 
mediated, at least in part, through the generation of 
fibronectin fragments. Interestingly, increases in 
fibronectin fragments containing the carboxyl-
terminal heparin binding domain, were also 
evident in the culture supernatants of cells treated 
with the HTRA1ΔmacSA. The fact that 
HTRA1ΔmacSA was proteolytically inactive and 
only able to generate fibronectin fragments in the 
presence of cells, would suggest that these effects 
were most likely mediated through the stimulated 
secretion of other active proteases. This may 
therefore offer some explanation as to why MMP 
production by IVD cells was enhanced with 
HTRA1ΔmacSA, although the mechanism of 
action still remains to be determined. Furthermore, 
the observation that levels of the 27-29 kDa 
fibronectin fragment containing the amino-
terminal fibrin- and heparin-binding domain were 
elevated predominantly in cell cultures treated 
with HTRA1Δmac, would further imply that these 
fragment species are of particular relevance with 
regards to IVD cell activation. 
Increased production of fibronectin by 
resident IVD cells has been observed within 
degenerated disc tissue samples and is considered 
to be central to the ongoing reparative and 
remodeling processes associated with IVD 
degeneration (30, 31). In the present study, we 
observed a marked increase in fibronectin 
expression in IVD tissue from patients with 
moderate to severe disc degeneration which 
correlated significantly with changes in HTRA1 
expression levels. At present, it is not known 
whether fibronectin and HTRA1 share common 
regulatory pathways, although it would appear that 
both their expression patterns are dependent on 
factors intrinsic to the degenerative process. Given 
the fact that HTRA1-generated fibronectin 
fragments serve as potent inducers of MMP 
production, overexpression of fibronectin and 
HTRA1 within IVDs is likely to have a significant 
influence on the development of disc 
degeneration. This is supported by our finding that 
small molecular weight fragments (27-29 kDa) 
containing the amino-terminal fibrin- and heparin-
binding domain of fibronectin, could also be 
identified within degenerated disc samples. The 
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involvement of such fragments in disc 
degeneration has already been alluded to in a 
recent report by Anderson et al. (32), where a 
single fibronectin fragment with an estimated size 
of 25 kDa was detected in degenerated discs by 
immunoblotting with the same monoclonal 
antibody as used in the current study. It is possible 
therefore, that HTRA1 protease activity may in 
fact be one of the main causative agents 
responsible for generating such fibronectin 
fragments within degenerated discs.  
Taken together, these findings led us to 
propose a working model for the biological role of 
HTRA1 in IVD degeneration (Fig. 6). In addition 
to its already well characterized ability to directly 
degrade ECM proteins known to be present within 
IVDs (19, 20, 33-35), HTRA1 may also further 
modulate ECM breakdown indirectly through 
fibronectin fragment production and subsequent 
upregulation of MMPs by resident disc cells.          
Clearly, further investigations are required in order 
to identify which particular fragments are 
responsible for the activation of IVD cells in vitro 
and to clarify the involvement of fibronectin 
fragments in IVD degeneration. Furthermore, 
additional studies are needed to fully evaluate the 
potential stimulatory effects of other soluble 
mediators (e.g. cytokines) released by IVD cells 
following incubation with HTRA1. Moreover, 
examination of the possible interplay between 
inflammatory mediators and fibronectin fragments 
in the regulation of toll-like receptor (TLR) 
signaling pathways in IVD cells, may also lend 
further insight into how HTRA1 contributes to the 
catabolic response in IVD degeneration (36). 
These results therefore encourage the 
design of specific HTRA1 inhibitors for the 
treatment of patients with disc degeneration, an 
endeavor which will no doubt be facilitated by 
information gleaned from the recently solved 
crystal structure of HTRA1 (37). 
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FIGURE 1. Detection of HTRA1 in human IVD tissue. A, HTRA1 mRNA levels in intact IVD tissue 
samples from patients (n = 36) with varying degrees of IVD degeneration were determined by qRT-PCR 
and presented as 2-∆CT, * p < 0.05, as determined by 1-way ANOVA (±S.E.M.). B, protein extracts from 
patient IVD tissues (n = 12) were loaded onto a 12% SDS-PAGE gel and immunoblotting performed 
using a polyclonal antibody specific for HTRA1; lane 1, HTRA1Δmac (4 ng) ; lanes 2 to 4, non-
degenerated (ND) discs; lanes 5 to 7, mildly degenerated discs; lanes 8 to 10, moderately degenerated 
discs; lanes 11 to 13, severely degenerated discs. 50 kDa HTRA1 (closed arrow head), 42 kDa HTRA1 
(open arrow head). C, representative images of HTRA1 protein within frozen IVD tissue sections as 
identified by immunofluorescence staining. HTRA1 was detected using a Cy3-labeled secondary antibody 
(red) and nuclei were labeled with DAPI (blue). The specificity of staining was confirmed through the use 
of a non-specific rabbit IgG control (IgG). Grade 1 represents a normal, non-degenerated IVD while 
grades 3 and 4 signify moderate and severe degeneration respectively. Scale bar = 50 µm. 
 
 
FIGURE 2. Regulation of MMP expression in IVD cells by recombinant HTRA1. A–B, recombinant 
HTRA1 proteolytic activity was determined using soluble bovine BODIPY FL-labeled DQ-elastin (100 
µg/ml) as a substrate. Digestion of the DQ-elastin yielded fluorescent fragments detectable at 530 nm by a 
fluorescence microplate reader. The amount of DQ-elastin digestion was measured at selected time points 
(0, 1, 2, 4 an 8 h) using a defined amount of HTRA1 (5 µg) (A) or was determined after incubation for 8 h 
with varying amounts of HTRA1 (0, 0.5, 1, 3 and 5 µg) (B). C–E, the effects of recombinant HTRA1 (5 
µg/ml) on MMP expression levels in IVD cells after a 24 h incubation period were determined by qRT-
PCR and the fold change as compared to untreated controls determined using the 2-∆∆CT method (n = 4-6 
patients). F, a specific MMP-3 ELISA was used to investigate the effects of recombinant HTRA1 on 
MMP protein secretion in supernatants obtained from IVD cells. (±S.D. triplicates). * p < 0.01 as 
determined by 1-way ANOVA.  
 
 
FIGURE 3. Downregulation of HTRA1-induced MMP expression in IVD cells by MEK inhibition. 
A, IL1B, IL6 and IL8 mRNA expression levels were measured in IVD cell cultures by qRT-PCR in 
response to HTRA1Δmac (5 µg/ml) stimulation over the course of 24 h and the fold change as compared 
to untreated cells determined using the 2-∆∆CT method. B, the influence of IL-1β inhibition on HTRA1-
induced MMP1 and MMP3 expression by IVD cells was evaluated by qRT-PCR after 24 h incubation 
with HTRA1Δmac (5 µg/ml) in combination with the IL-1RA (250 ng/ml) and the fold change as 
compared to untreated controls determined using the 2-∆∆CT method. C, the effects of MEK inhibitors 
PD98059 (10 µM) and U0126 (10 µM) on HTRA1-induced MMP1 and MMP3 expression by IVD cells 
was evaluated by qRT-PCR after a 24 h incubation and the fold change as compared to untreated controls 
determined using the 2-∆∆CT method. In each case, data is representative of at least two separate 
experiments performed using IVD cells isolated from a total of n = 5 patients.  (±S.D. triplicates). * p < 
0.01 as determined by 1-way ANOVA. 
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FIGURE 4. Stimulation of IVD cells with HTRA1-generated fibronectin fragments. A, concentrated 
protein supernatants (15 µg) from IVD cells treated for 24 h without or with HTRA1Δmac (5 µg/ml) or 
HTRA1ΔmacSA (5 µg/ml) were subjected to immunoblotting using antibodies Mab 1935 specific for the 
fibronectin carboxyl-terminal heparin binding domain (C-terminus) or Mab 1936 specific for the 
fibronectin amino-terminal fibrin- and heparin-binding domain (N-terminus). Fibronectin fragments 
containing the amino-terminal fibrin- and heparin-binding domain are identified by the closed arrow 
head. B, purified human plasma-derived fibronectin (Fn) was incubated with HTRA1Δmac or 
HTRA1ΔmacSA at equimolar concentrations in Tris buffered saline (TBS), pH 8.5, for 16 h at 37oC and 
samples loaded onto a 4-15% gradient gel and stained with Coomassie Blue. Fibronectin and recombinant 
HTRA1 alone were also loaded and served as controls. C, an equimolar concentration of human plasma-
derived fibronectin and HTRA1Δmac were incubated for 16 h and fibronectin fragments visualized by 
Western blot analysis using the antibodies described in panel A. D, equimolar concentrations of 
fibronectin (20 µg) and HTRA1Δmac (5 µg) were incubated for 16 h and fibronectin fragments purified 
by affinity chromatography. IVD cells were incubated with purified HTRA1-digested fibronectin 
(Fn+HTRA1Δmac) for 24 h and expression levels of MMP1, MMP3, and MMP13 mRNA determined by 
qRT-PCR and the fold change as compared to untreated controls determined using the 2-∆∆CT method. 
Additional cultures were incubated with either affinity purified Tris buffered saline, pH 7.6 (TBS), 
fibronectin (Fn), HTRA1 (HTRA1Δmac - fibronectin) or left untreated (control). Data is representative of 
two separate experiments performed using IVD cells from two patients.  (±S.D. triplicates). * p < 0.01 as 
determined by 1-way ANOVA. 
 
 
FIGURE 5. Detection of fibronectin fragments in degenerated IVD tissue. A, fibronectin (FN) mRNA 
levels in intact IVD tissue samples from patients (n = 36) with varying degrees of IVD degeneration were 
determined by qRT-PCR and presented as 2-∆CT, (±S.E.M.). B, correlation study between FN and HTRA1 
mRNA levels (2-∆CT) in patient IVD tissue samples (n = 36), R2, square of correlation coefficient, p < 0.01 
as determined from Pearson’s correlation coefficient. C, protein extracts from patient IVD tissues (n = 12) 
were loaded onto a 12% SDS-PAGE gel and immunoblotting performed using a monoclonal antibody 
(Mab1936) specific for the amino-terminal fibrin- and heparin-binding domain. D, the PVDF membrane 
used in panel C was stained with Coomassie Blue in order to confirm equal protein loading. Lane 1, 
HTRA1-digested human plasma-derived fibronectin; lanes 2 to 4, non-degenerated (ND) discs; lanes 5 to 
7, mildly degenerated discs; lanes 8 to 10, moderately degenerated discs; lanes 11 to 13, severely 
degenerated discs.  
 
 
FIGURE 6. A theoretical model for the role of HTRA1 in IVD degeneration. Based on our findings, 
we propose that HTRA1 accumulates in IVD tissue undergoing degeneration, and stimulates MMP 
production by resident cells in a predominantly protease-dependent manner, via activation of the MEK 
pathway. Furthermore, we suggest that the stimulatory effects of HTRA1 on IVD cells are mediated 
indirectly through its ability to generate fibronectin fragments, although other routes of cellular activation 
cannot be ruled out. IDD, intervertebral disc degeneration. 
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Table 1. rs11200638 SNP Genotyping of European Patients with and without IVD Degeneration  
 Degeneration grade   Relative HTRA1 
expression c 
 
Genotype 1 (n=8) 2 (n=7) 3 (n=10) 4 (n=10)  n p-value d 
GG 5 5 7 7  23 204.1 ± 35.6  
GA 2 2 3 3  8 307 ± 87.3 0.20 
AA 1 0 0 0  1 14.9  
GA+AA 3  2  3  3   9 274.5 ± 83.5 0.37 
G allele 12 12 17 17     
A allele a 4 (25%) 2 (14.3%) 
p = 0.4b 
3 (15%)  
p = 0.37b 
3 (15%) 
p = 0.37b 
    
a Percentages refer to risk allele (A) frequency; b the chi-square test (χ2) was used to evaluate the 
significance of differences in risk allele (A) frequency between patients with IVD degeneration (grades 2 
to 4) and control patients without IVD degeneration (grade 1) (n = 35); c comparisons were made between 
HTRA1 expression levels (± S.E.M.) in IVD tissue and genotype frequency in patients where both RNA 
and DNA samples were available (n = 32); d Student’s t-test was used to compare HTRA1 expression 
levels between patients carrying the risk allele (GA/AA) and those homozygous for the wild type allele 
(GG). 
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